Clinical trials: Non-Hodgkin
Lymphoma, B-Cell, Lymphoma, T-Cell
A Phase 1/2 Study of STP938 (Dencatistat) for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas
The Phase 1 part of the study is a dose escalation of STP938 as monotherapy. The Phase 2 part of the study is cohort expansion of STP938 as a monotherapy in 5 different B and T cell lymphomas.
- Trial name
- NCT05463263
- Testing
- STP938
- Where
- 15 sites in United States, France and 1 more
- Volunteers
- 180 people
- Sponsor
- Step Pharma, SAS
Hodgkin Disease, Lymphoma, Large-cell, Anaplastic
A Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian Federation
The purpose of this study is to describe patterns of treatment used for cHL and sALCL in real world setting.
- Trial name
- KLIO (NCT03942263)
- Where
- 50 sites in Russia
- Volunteers
- 2,000 people
- Sponsor
- Takeda
Lymphoma, Large B-Cell, Diffuse
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells.
- Trial name
- NCT06890884
- Testing
- Zilovertamab vedotin, Rituximab, Cyclophosphamide
- Where
- 148 sites in United States, Belgium and 7 more
- Volunteers
- 594 people
- Sponsor
- Merck Sharp & Dohme LLC
Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma
A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers
The purpose of this study is to learn about the effects of a new study medicine called PF-08046032, when taken alone and when taken with another medicine called sasanlimab, for the treatment of advanced cancers.
- Conditions
- Peripheral T Cell Lymphoma, Diffuse Large B-cell Lymphoma, Classical Hodgkin Lymphoma, Head and Neck Squamous Cell Carcinoma
- Trial name
- NCT06870487
- Testing
- PF-08046032, Sasanlimab
- Where
- 4 sites in United States, Spain
- Volunteers
- 6 people
- Sponsor
- Pfizer
Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma
Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma
The purpose of this study is to evaluate the objective response rate (ORR) of E7777 in participants with relapsed or refractory peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).
- Trial name
- NCT02676778
- Testing
- E7777
- Where
- 20 sites in Japan
- Volunteers
- 45 people
- Sponsor
- Eisai Co., Ltd.
Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL), Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if…
- Trial name
- NCT06393738
- Testing
- ARV-393, Glofitamab
- Where
- 21 sites in United States, Australia and 3 more
- Volunteers
- 329 people
- Sponsor
- Arvinas Inc.
Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
This is a phase 2, Open-label, to investigate the efficacy and safety of IMC-001 in patients with Relapsed or Refractory extranodal NK/T cell lymphoma, nasal type
- Trial name
- NCT04414163
- Testing
- IMC-001
- Where
- 5 sites in South Korea
- Volunteers
- 23 people
- Sponsor
- ImmuneOncia Therapeutics Inc.
Mantle Cell Lymphoma
A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy
The purpose of this study is to evaluate the efficacy and safety of ibrutinib in patients with mantle cell lymphoma who received at least 1 prior rituximab-containing chemotherapy regimen and who progressed after bortezomib…
- Trial name
- NCT01599949
- Testing
- Ibrutinib
- Where
- 56 sites in United States, Belgium and 7 more
- Volunteers
- 120 people
- Sponsor
- Janssen Research & Development, LLC
Hodgkin Lymphoma, Peripheral T Cell Lymphoma
A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
This study will look at whether brentuximab vedotin works and is safe in the re-treatment setting. To be in this study, patients must have already received brentuximab vedotin as treatment and have cancer that progressed (got…
- Conditions
- Hodgkin Lymphoma, Peripheral T Cell Lymphoma, Anaplastic Large Cell Lymphoma
- Trial name
- NCT03947255
- Testing
- brentuximab vedotin
- Where
- 19 sites in United States
- Volunteers
- 12 people
- Sponsor
- Seagen Inc.
Mantle Cell Lymphoma (MCL)
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
This is an open-label, single arm, multi-center Phase 2 study of oral Rocbrutinib in patients with mantle cell lymphoma who are failed or relapsed after remission or intolerated to Bruton's tyrosine kinase (BTK) inhibitor.
- Trial name
- NCT05716087
- Testing
- Rocbrutinib
- Where
- 43 sites in China
- Volunteers
- 62 people
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
Lymphoma
Monoclonal Antibodies in Detecting Residual Disease in Patients Who Have Been Treated for Non-Hodgkin's Lymphoma
RATIONALE: Diagnostic imaging procedures, such as radiolabeled monoclonal antibodies, may improve the ability to detect the residual disease in patients who have been treated for non-Hodgkin's lymphoma.
- Trial name
- NCT00003338
- Testing
- immunoscintigraphy, technetium Tc 99m epratuzumab
- Where
- 8 sites in United States, Austria and 3 more
- Volunteers
- 60 people
- Sponsor
- Gilead Sciences
Diffuse Large B-Cell Lymphoma, Unspecified Site
A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients
A Multi-center, Randomized, Double-blind, Controlled, and Parallel Phase III Study to Compare the Efficacy and Safety of GB241 (Recombinant Anti-CD20 Human-Mouse Chimeric Monoclonal Antibody Injection, Experimental Drug) Plus…
- Trial name
- NCT03650933
- Testing
- G-CHOP, R-CHOP
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Nanjing Yoko Biomedical Co., Ltd.
Mycosis Fungoides, Cutaneous T-cell Lymphoma
A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides
This study will evaluate the safety and preliminary efficacy of duvelisib topical gel in participants with early-stage mycosis fungoides.
- Trial name
- NCT07714187
- Testing
- Duvelisib
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- SecuraBio
Diffuse Non-Hodgkin Lymphoma
A Clinical Trial of CNCT19 Cells in the Treatment of CD19 Positive Relapsed or Refractory Diffuse Non-Hodgkin Lymphoma
This is a single arm, open-label, non-randomized, dose-escalation, phase I study to determine the safety and efficacy of CNCT19 in adult patients with relapsed or refractory diffuse Non-Hodgkin lymphoma.
- Trial name
- NCT04232826
- Testing
- single dose of CNCT19
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Juventas Cell Therapy Ltd.
Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma
Study to Evaluate the Safety and Efficacy of Tafasitamab Plus Lenalidomide in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
The purpose of this study is to assess the efficacy and safety of of tafasitamab plus lenalidomide in adults with diffuse large B-cell lymphoma (DLBCL) who have relapsed or are refractory to at least 1 but no more than 3 previous…
- Trial name
- firmMIND (NCT05429268)
- Testing
- Tafasitamab, Lenalidomide
- Where
- 61 sites in Bulgaria, Croatia and 12 more
- Volunteers
- 82 people
- Sponsor
- Incyte Corporation
Relapsed/Refractory Aggressive B-Cell Malignancies
A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies
This is a Phase 1/2 study to investigate the safety and efficacy of the CAR-T therapy, ONCT-808, in patients with relapsed/refractory (R/R) aggressive B cell malignancies.
- Trial name
- NCT05588440
- Testing
- ONCT-808, Bridging Therapy
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Oncternal Therapeutics, Inc
Neoplasms, Hodgkin's Disease
Study of TPI 287 Administered Every 21 Days in Patients With Advanced Malignancies
Tapestry Pharmaceuticals, Inc. has developed a novel taxane analog, TPI 287. TPI 287 is synthetically manufactured from naturally occurring taxanes extracted from yew starting material.
- Conditions
- Neoplasms, Hodgkin's Disease, Non-Hodgkin's Lymphoma
- Trial name
- NCT00256191
- Testing
- TPI 287 Injection
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Cortice Biosciences, Inc.
B-cell Non Hodgkin's Lymphoma
Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.
The purpose of this study is to determine whether SCT400 is safe and effective in the treatment of B-cell Non Hodgkin's lymphoma
- Trial name
- NCT02206308
- Testing
- Chimeric anti-CD20 monoclonal antibody
- Volunteers
- 15 people
- Sponsor
- Sinocelltech Ltd.
Mantle Cell Lymphoma, B Cell Lymphoma
Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma
This is a Phase 2 study to determine the efficacy and safety of canfosfamide treatment in relapsed or refractory mantle cell lymphoma, diffuse large B cell lymphoma and multiple myeloma.
- Conditions
- Mantle Cell Lymphoma, B Cell Lymphoma, Multiple Myeloma
- Trial name
- NCT01148108
- Testing
- Canfosfamide HCl for injection
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Telik
Lymphoma, Non-Hodgkin's
Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma
The purpose of the study is to evaluate the mechanism(s) of action of galiximab in subjects with previously untreated follicular NHL.
- Trial name
- NCT00651443
- Testing
- Galiximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Biogen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.